Your browser doesn't support javascript.
loading
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial.
Berry, Donna L; Hong, Fangxin; Blonquist, Traci M; Halpenny, Barbara; Xiong, Niya; Filson, Christopher P; Master, Viraj A; Sanda, Martin G; Chang, Peter; Chien, Gary W; Jones, Randy A; Krupski, Tracey L; Wolpin, Seth; Wilson, Leslie; Hayes, Julia H; Trinh, Quoc-Dien; Sokoloff, Mitchell.
Afiliación
  • Berry DL; Dana-Farber Cancer Institute, Boston, MA; University of Washington School of Nursing, Seattle, WA. Electronic address: donnalb@uw.edu.
  • Hong F; Dana-Farber Cancer Institute, Boston, MA.
  • Blonquist TM; Dana-Farber Cancer Institute, Boston, MA.
  • Halpenny B; Dana-Farber Cancer Institute, Boston, MA.
  • Xiong N; Dana-Farber Cancer Institute, Boston, MA.
  • Filson CP; Department of Urology, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute, Emory Healthcare, Atlanta, GA; Atlanta VA Medical Center, Decatur, GA.
  • Master VA; Department of Urology, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute, Emory Healthcare, Atlanta, GA.
  • Sanda MG; Department of Urology, Emory University School of Medicine, Atlanta, GA.
  • Chang P; Beth Israel Deaconess Medical Center, Boston, MA.
  • Chien GW; Department of Urology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.
  • Jones RA; University of Virginia School of Nursing, Charlottesville, VA.
  • Krupski TL; University of Virginia School of Medicine, Charlottesville, VA.
  • Wolpin S; University of Washington School of Nursing, Seattle, WA.
  • Wilson L; Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA.
  • Hayes JH; Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, MA.
  • Trinh QD; Department of Urology, Brigham and Women's Hospital, Boston, MA.
  • Sokoloff M; Department of Urology, University of Massachusetts Medical Center, Worchester, MA.
Urol Oncol ; 39(8): 493.e9-493.e15, 2021 08.
Article en En | MEDLINE | ID: mdl-33353864
INTRODUCTION: Men diagnosed with localized prostate cancer must navigate a highly preference-sensitive decision between treatment options with varying adverse outcome profiles. We evaluated whether use of a decision support tool previously shown to decrease decisional conflict also impacted the secondary outcome of post-treatment decision regret. METHODS: Participants were randomized to receive personalized decision support via the Personal Patient Profile-Prostate or usual care prior to a final treatment decision. Symptoms were measured just before randomization and 6 months later; decision regret was measured at 6 months along with records review to ascertain treatment choices. Regression modeling explored associations between baseline variables including race and D`Amico risk, study group, and 6-month variables regret, choice, and symptoms. RESULTS: At 6 months, 287 of 392 (73%) men returned questionnaires of which 257 (89%) had made a treatment choice. Of that group, 201 of 257 (78%) completely answered the regret scale. Regret was not significantly different between participants randomized to the P3P intervention compared to the control group (P = 0.360). In univariate analyses, we found that Black men, men with hormonal symptoms, and men with bowel symptoms reported significantly higher decision regret (all P < 0.01). Significant interactions were detected between race and study group (intervention vs. usual care) in the multivariable model; use of the Personal Patient Profile-Prostate was associated with significantly decreased decisional regret among Black men (P = 0.037). Interactions between regret, symptoms and treatment revealed that (1) men choosing definitive treatment and reporting no hormonal symptoms reported lower regret compared to all others; and (2) men choosing active surveillance and reporting bowel symptoms had higher regret compared to all others. CONCLUSION: The Personal Patient Profile-Prostate decision support tool may be most beneficial in minimizing decisional regret for Black men considering treatment options for newly-diagnosed prostate cancer. TRIAL REGISTRATION: NCT01844999.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Conducta de Elección / Técnicas de Apoyo para la Decisión / Toma de Decisiones / Emociones / Efectos Adversos a Largo Plazo Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Límite: Humans / Male Idioma: En Revista: Urol Oncol Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Conducta de Elección / Técnicas de Apoyo para la Decisión / Toma de Decisiones / Emociones / Efectos Adversos a Largo Plazo Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Límite: Humans / Male Idioma: En Revista: Urol Oncol Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article
...